fig6

Figure 6. In vivo toxicity of various treatments against 4T1 tumor. (A) Scheme for establishing a 4T1 tumor-bearing mouse model and treatments in vivo; (B) Scheme of ICD caused by G/T@L-E; (C) Tumor volumes after different treatments. n = 6; (D) Representative tumor image of the harvested 4T1 tumors following various treatments after 14 days; (E) Tumor weights after different treatments. n = 6; (F) Body weights after different treatments. n = 6; (G) H&E staining, Ki-67, and TUNEL of tumor tissues after different treatments. Scale bar: 100 µm; (H) Immunofluorescence images of HSP70, CRT, and HMGB1 from tumor tissue following various treatments. Scale bar: 100 μm; (I) The corresponding fluorescence intensities of HSP70 quantified by ImageJ software. n = 3; (J) The corresponding fluorescence intensities of CRT quantified by ImageJ software. n = 3 (The groups are defined as follows: G1: PBS; G2: E. coli; G3: G@L-E; G4: T@L-E; G5: G/T@L; G6: G/T@L-E). Data are presented as mean ± SD. Significance was compared by two-way ANOVA followed by Tukey’s multiple comparisons test. ^****P < 0.0001. Some elements in (A and B) were created with BioRender.com. ICD: Immunogenic cell death; HSP70: heat shock protein 70; CRT: calreticulin; HMGB1: high mobility group box 1; PBS: phosphate-buffered saline; SD: standard deviation; ANOVA: analysis of variance; GOx: glucose oxidase; ROS: reactive oxygen species; TPZ: Tirapazamine; E. coli: Escherichia coli; DAPI: 4′,6-diamidino-2-phenylindole.